Artiva Biotherapeutics (ARTV) to Release Earnings on Thursday

Key Points

• Artiva Biotherapeutics (ARTV) will release Q1 2026 results before the market opens on Thursday, May 14, with analysts forecasting ($0.88) EPS; an earnings call is scheduled for Wednesday, May 13 at 9:30 AM ET.
• Shares jumped 16.9% to open at $12.39, giving the company a market cap of about $306.3 million; the stock’s 52‑week range is $1.47 to $14.53 and its 50‑/200‑day moving averages are $7.44/$5.30.
• Analyst sentiment is mixed — MarketBeat shows a consensus “Moderate Buy” with a $18.67 target while individual firms range from Strong Buy to Sell — and several institutional investors have recently established or increased small positions in ARTV.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.03. On average, analysts expect Artiva Biotherapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Stock Up 16.9%

ARTV opened at $12.39 on Thursday. The stock's fifty day moving average is $7.44 and its two-hundred day moving average is $5.30. The company has a market capitalization of $306.28 million, a P/E ratio of -3.62 and a beta of 2.86. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $14.53.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently bought and sold shares of ARTV. Prelude Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Bank of America Corp DE increased its position in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock worth $46,000 after acquiring an additional 11,190 shares during the period. Bridgeway Capital Management LLC purchased a new position in Artiva Biotherapeutics in the second quarter valued at $53,000. Qube Research & Technologies Ltd purchased a new position in Artiva Biotherapeutics in the second quarter valued at $58,000. Finally, Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the second quarter valued at $67,000.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Needham & Company LLC reiterated a "buy" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a report on Monday. Finally, Wall Street Zen downgraded Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Artiva Biotherapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $18.67.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.